140 related articles for article (PubMed ID: 38224148)
1. Impact of Neoadjuvant Therapy for Pancreatic Cancer: Transatlantic Trend and Postoperative Outcomes Analysis.
Davis CH; Augustinus S; de Graaf N; Wellner UF; Johansen K; Andersson B; Beane JD; Björnsson B; Busch OR; Gleeson EM; van Santvoort HC; Tingstedt B; Williamsson C; Keck T; Besselink MG; Koerkamp BG; Pitt HA;
J Am Coll Surg; 2024 Apr; 238(4):613-621. PubMed ID: 38224148
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Therapy for Pancreatic Cancer: Increased Use and Improved Optimal Outcomes.
Davis CH; Beane JD; Gazivoda VP; Grandhi MS; Greenbaum AA; Kennedy TJ; Langan RC; August DA; Alexander HR; Pitt HA
J Am Coll Surg; 2022 Apr; 234(4):436-443. PubMed ID: 35290262
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Propensity-Matched Analysis of Postoperative Complications Using ACS-NSQIP.
Krell RW; McNeil LR; Yanala UR; Are C; Reames BN
Ann Surg Oncol; 2021 Jul; 28(7):3810-3822. PubMed ID: 33386542
[TBL] [Abstract][Full Text] [Related]
4. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.
Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB
J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330
[TBL] [Abstract][Full Text] [Related]
5. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
Sternby H; Andersson B
Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
[TBL] [Abstract][Full Text] [Related]
6. Comparing Post-Operative Outcomes of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Neoadjuvant Therapy Versus Surgery First Approach.
Hyman DW; Almerey T; Mujkanovic A; Hammons I; Tice M; Stauffer JA
Am Surg; 2022 Aug; 88(8):1868-1874. PubMed ID: 35465681
[TBL] [Abstract][Full Text] [Related]
7. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications.
Marchegiani G; Andrianello S; Nessi C; Sandini M; Maggino L; Malleo G; Paiella S; Polati E; Bassi C; Salvia R
Ann Surg Oncol; 2018 Mar; 25(3):626-637. PubMed ID: 29214453
[TBL] [Abstract][Full Text] [Related]
9. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
10. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
11. Upfront Surgery and Surgery Following Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: A Comparative Analysis of Short-term Postoperative Outcomes.
Jung JH; Yoon SK; Yoon SJ; Shin SH; Han IW; Heo JS
Anticancer Res; 2021 Nov; 41(11):5703-5712. PubMed ID: 34732443
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma is Associated with Lower Post-Pancreatectomy Readmission Rates: A Population-Based Cohort Study.
Kamarajah SK; Naffouje SA; Salti GI; Dahdaleh FS
Ann Surg Oncol; 2021 Apr; 28(4):1896-1905. PubMed ID: 33398644
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis.
Machairas N; Raptis DA; Velázquez PS; Sauvanet A; Rueda de Leon A; Oba A; Koerkamp BG; Lovasik B; Chan C; Yeo CJ; Bassi C; Ferrone CR; Kooby D; Moskal D; Tamburrino D; Yoon DS; Barroso E; de Santibañes E; Kauffmann EF; Vigia E; Robin F; Casciani F; Burdío F; Belfiori G; Malleo G; Lavu H; Hartog H; Hwang HK; Han HS; Marques HP; Poves I; Domínguez-Rosado I; Park JS; Lillemoe KD; Roberts K; Sulpice L; Besselink MG; Abuawwad M; Del Chiaro M; de Santibañes M; Falconi M; D'Silva M; Silva M; Hilal MA; Qadan M; Sell NM; Beghdadi N; Napoli N; Busch ORC; Mazza O; Muiesan P; Müller PC; Ravikumar R; Schulick R; Powell-Brett S; Abbas SH; Mackay TM; Stoop TF; Gallagher TK; Boggi U; van Eijck C; Clavien PA; Conlon KCP; Fusai GK
Ann Surg; 2021 Nov; 274(5):721-728. PubMed ID: 34353988
[TBL] [Abstract][Full Text] [Related]
14. Evolving management of early stage pancreatic adenocarcinoma in older patients.
Nassoiy S; Christopher W; Marcus R; Keller J; Weiss J; Chang SC; Essner R; Foshag L; Fischer T; Goldfarb M
Am J Surg; 2023 Jan; 225(1):212-219. PubMed ID: 36058752
[TBL] [Abstract][Full Text] [Related]
15. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium.
Ogobuiro I; Collier AL; Khan K; de Castro Silva I; Kwon D; Wilson GC; Schwartz PB; Parikh AA; Hammill C; Kim HJ; Kooby DA; Abbott D; Maithel SK; Snyder RA; Ahmad SA; Merchant NB; Datta J
Ann Surg Oncol; 2023 Mar; 30(3):1485-1494. PubMed ID: 36316508
[TBL] [Abstract][Full Text] [Related]
16. Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
Rieser CJ; Zenati M; Narayanan S; Bahary N; Lee KK; Paniccia A; Bartlett DL; Zureikat AH
Ann Surg Oncol; 2021 Oct; 28(11):6264-6272. PubMed ID: 33748894
[TBL] [Abstract][Full Text] [Related]
17. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
[TBL] [Abstract][Full Text] [Related]
18. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment.
Leonhardt CS; Pils D; Qadan M; Jomrich G; Assawasirisin C; Klaiber U; Sahora K; Warshaw AL; Ferrone CR; Schindl M; Lillemoe KD; Strobel O; Fernández-Del Castillo C; Hank T
Ann Surg; 2024 Feb; 279(2):314-322. PubMed ID: 37042245
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
[TBL] [Abstract][Full Text] [Related]
20. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer.
Leonhardt CS; Pils D; Qadan M; Gustorff C; Sahora K; Klaiber U; Warshaw AL; Prager G; Ferrone CR; Lillemoe KD; Schindl M; Strobel O; Castillo CF; Hank T
Eur J Cancer; 2023 Nov; 193():113293. PubMed ID: 37713740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
